ReviewMolecular and cellular biochemistry2026
Advances in MicroRNA-Based Therapies for Cardiac Repair: Emerging Strategies for Treating Myocardial Infarction.
Review in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA Expression and Carotid Plaque Vulnerability: An Exploratory Tissue-Based Study.Journal of personalized medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Myocardial infarction (MI) continues to be a major cause of mortality worldwide, highlighting the need for immediate investigation into novel therapeutic approaches for repairing damaged heart tissue. MicroRNAs (miRNAs) have become essential regulators of different biological processes, including heart development, MI development, and cardiac repair after MI. This review seeks to elucidate the complex functions of miRNAs in MI development and cardiac regeneration/repair after MI, emphasizing their role in regulating different stages related to MI, such as inflammation, apoptosis, angiogenesis, and fibrosis. We also reviewed the advances in the regulation of particular miRNAs in the MI and their potential as therapeutic agents for evaluating cardiac recovery. Furthermore, we summarised the encouraging developments in miRNA-based therapeutics, in vitro growth of cardiomyocytes (CMs) for cell therapy of MI. Understanding the various functions that miRNAs perform in the heart's repair process following MI offers a great deal of promise for developing therapeutic approaches that can improve patient outcomes and mitigate the effects of heart failure.
Indexed as
Identifiers
41557128What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.